SEARCH

SEARCH BY CITATION

References

  • 1
    Albores-saavedra J, Scoazec JC, Wittekind C et al. World Health Organization Classification of tumors, Pathology and Genetics, Tumor of the Digestive System; Carcinoma of the gallbladder and extrahepatic bile ducts. Lyon: International Agency for Research on Cancer, 2000.
  • 2
    Yamato T, Sasaki M, Watanabe Y, Nakanuma Y. Expression of MUC1 and MUC2 mucin core proteins and their messenger RNA in gall bladder carcinoma: an immunohistochemical and in situ hybridization study. J Pathol 1999; 188: 307.
  • 3
    Sasaki M, Yamato T, Nakanuma Y, Ho SB, Kim YS. Expression of MUC2, MUC5AC and MUC6 apomucins in carcinoma, dysplasia and non-dysplastic epithelia of the gallbladder. Pathol Int 1999; 49: 3844.
  • 4
    Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21 (WAF1) involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 12411246.
  • 5
    Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 8490.
  • 6
    Sasaki M, Yamaguchi J, Itatsu K, Ikeda H, Nakanuma Y. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol 2008; 215: 17583.
  • 7
    Valk-Lingbeek ME, Bruggeman SW, Van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004; 118: 40918.
  • 8
    Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 2002; 16: 28932905.
  • 9
    Van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 1999; 23: 474478.
  • 10
    Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 53235335.
  • 11
    Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 2005; 24: 62696280.
  • 12
    Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624629.
  • 13
    Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Can Inst 2003; 95: 661668.
  • 14
    Collett K, Eide GE, Arnes J et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006; 12: 11681174.
  • 15
    Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 1160611611.
  • 16
    Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Advances in Cancer Research 2002; 86: 4165.
  • 17
    Mai A, Massa S, Rotili D et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Medic Res Rev 2005; 25: 261309.
  • 18
    Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005; 23: 39713993.
  • 19
    Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 55415552.
  • 20
    Ungerstedt JS, Sowa Y, Xu WS et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 673678.
  • 21
    Burgess A, Ruefli A, Beamish H et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004; 23: 66936701.
  • 22
    Garcia P, Manterola C, Araya JC et al. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesion. Mol Carcinog 2009; 48: 7989.
  • 23
    Takahashi T, Shicapurkar N, Riquelme E et al. Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res 2004; 10: 61266133.
  • 24
    Yamaguchi J, Sasaki M, Harada K et al. Papillary hyperplasia of the gallbladder in pancreatobiliary maljunction represents a senescence-related lesion induced by lysolecithin. Lab Invest 2009; 89: 10181031.
  • 25
    Xu LN, Wang X, Zou SQ. Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines. World J Gastroenterol 2008; 14: 25782581.
  • 26
    Harada K, Ohba K, Ozaki S et al. Peptide antibiotic human beta-defensin-1 and -2 contribute to antimicrobial defense of the intrahepatic biliary tree. Hepatology 2004; 40: 925932.
  • 27
    Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4a tumor suppressor gene. Genes Dev 2007; 21: 4954.
  • 28
    Cao Q, Yu J, Dhanasekaran SM et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27: 72747284.
  • 29
    Egger G, Liang GN, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457463.
  • 30
    Sparmann A, Van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6: 846856.
  • 31
    Rea S, Eisenhaber F, O’Carroll N et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000; 406: 593599.
  • 32
    Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 2008; 10: 10211027.
  • 33
    Weichert W, Roske A, Niesporek S et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008; 14: 16691677.
  • 34
    Lin ZH, Bazzaro M, Wang MC, Chan KC, Peng SW, Roden RBS. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 2009; 15: 570577.
  • 35
    Fujii S, Ito K, Ito Y, Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 2008; 283: 1732417332.
  • 36
    Bracken AP, Kleine-Kohlbrecher D, Dietrich N et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007; 21: 525530.
  • 37
    Fiskus W, Pranpat M, Balasis M et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 2006; 5: 30963104.
  • 38
    Tan J, Yang XJ, Zhuang L et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21: 10501063.